Some of the most effective and expensive cancer drugs, dubbed “smart drugs” for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, researchers examined one such driver, the EGF receptor (EGFR), and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.